Abstract | OBJECTIVE: RESEARCH DESIGN AND METHODS: In the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) study, a cardiovascular safety study of sitagliptin, all suspected cases of acute pancreatitis and pancreatic cancer were collected prospectively for 14,671 participants during a median follow-up time of 3 years, and were adjudicated blindly. RESULTS: Baseline differences were minimal between participants confirmed to have no pancreatic events, acute pancreatitis, or pancreatic cancer. Among those participants randomized to receive sitagliptin, 23 (0.3%) (vs. 12 randomized to receive placebo [0.2%]) had pancreatitis (hazard ratio 1.93 [95% CI 0.96-3.88], P = 0.065; 0.107 vs. 0.056/100 patient-years), with 25 versus 17 events, respectively. Severe pancreatitis (two fatal) occurred in four individuals allocated to receive sitagliptin. Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28-1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years). Meta-analysis with two other DPP-4i cardiovascular outcome studies showed an increased risk for acute pancreatitis (risk ratio 1.78 [95% CI 1.13-2.81], P = 0.01) and no significant effect for pancreatic cancer (risk ratio 0.54 [95% CI 0.28-1.04], P = 0.07). CONCLUSIONS:
|
Authors | John B Buse, M Angelyn Bethel, Jennifer B Green, Susanna R Stevens, Yuliya Lokhnygina, Pablo Aschner, Carlos Raffo Grado, Tsvetalina Tankova, Julio Wainstein, Robert Josse, John M Lachin, Samuel S Engel, Keyur Patel, Eric D Peterson, Rury R Holman, TECOS Study Group |
Journal | Diabetes care
(Diabetes Care)
Vol. 40
Issue 2
Pg. 164-170
(Feb 2017)
ISSN: 1935-5548 [Electronic] United States |
PMID | 27630212
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2017 by the American Diabetes Association. |
Chemical References |
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
|
Topics |
- Acute Disease
- Aged
- Cardiovascular Diseases
(drug therapy)
- Diabetes Mellitus, Type 2
(drug therapy)
- Dipeptidyl-Peptidase IV Inhibitors
(administration & dosage, adverse effects)
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Pancreatic Neoplasms
(chemically induced, diagnosis)
- Pancreatitis
(chemically induced, diagnosis)
- Proportional Hazards Models
- Risk Factors
- Sitagliptin Phosphate
(administration & dosage, adverse effects)
- Treatment Outcome
|